title: Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
authors.affiliation: Department of Cardiology, MD Anderson Cancer Center, Houston, Texas, USA mewer@mdanderson.org.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Ewer
authors.affiliation: The Washington Cancer Institute, Washington, D.C., USA.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D018943:Anthracyclines; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
keywords: Anthracycline cardiotoxicity; Breast cancer clinical trials; Dual anti-HER2 cardiotoxicity; Trastuzumab cardiac dysfunction